Firas Petros, MD

Dr. Petros reputation is built upon several high-level academic and clinical roles:

• Clinical Leadership: Prior to joining the Cleveland Clinic, he served as the Chief of Urologic Oncology at the University of Toledo and had a joint appointment as an Associate Professor in Urology and Medicine.
• Research Prominence: While practicing at the University of Toledo, Dr. Petros held the Frank Stranahan Endowed Chair for Oncologic Research and was the Director of the Precision Oncology Research Program. He established genitourinary clinical trials at Eleanor N. Dana Cancer Center where he served as the Principal Investigator (PI) for national and international phase II and Phase III clinical trials. He was able to recruit and enroll patients with high-risk cancers, some of whom failed traditional therapies. Dr. Petros’ role extended to overseeing all cancer trials in coordination with monitors from sponsoring companies as he spearheaded a research team of coordinators, data managers, and research pharmacists in compliance with regulatory bodies such as IRBs and FDA. With an h-index of 23 and more than 1580 citations, Dr. Petros has co-authored over 80 peer-reviewed articles, book chapters, editorials, and surgical videos, specifically advancing treatment for urologic cancers focusing on Renal Cell Carcinoma (RCC) and rare cancers such as Upper Tract Urothelial Carcinoma (UTUC).

Highly Rated: MediFind recognizes Dr. Petros as a Distinguished Provider for UTUC, ranking him among the top specialists for the condition based on clinical research and outcomes. Dr. Petros has been serving as an abstract and video reviewer for the American Urological Association (AUA) and has been an invited speaker and panelist at numerous regional and national meetings. You can access video and news showcasing Dr. Petros from the following link. Dr. Petros was chosen by the AUA as an external reviewer of AUA/SUO Guidelines for UTUC published in 2023. Importantly, these first-ever guidelines have made several recommendations based on a number of seminal studies published by Dr. Petros.

• Elite Training: His renown is supported by a Urologic Oncology fellowship at the prestigious MD Anderson Cancer Center, one of the top cancer centers in the world.
• Education and mentorship: Dr. Petros provides exceptional mentorship to multiple levels of medical trainees (fellows, residents, and medical students) interested in the field of urologic oncology and has lectured at the medical school.
• Long-Standing Practice: With over 20 years of experience, he is a board-certified urologist and a fellow of the American College of Surgeons (F.A.C.S.).

Additionally, Dr. Petros completed Research and Clinical Fellowships in Robotic and Minimally Invasive Urologic Surgery at the Vattikuti Urology Institute at Henry Ford Health System, Detroit, Michigan.

Dr. Petros has received multiple awards in recognition of his contributions to advancing research at regional, national and international meetings.

Dr. Petros is an active member of several professional societies and associations including American Urological Association, (AUA), American College of Surgeons, (ACS), Society of Urologic Oncology (SUO), North Central Section of AUA (NCS), and Ohio Urologic Society (OUS).

See publications for this provider. (Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)

Cleveland Clinic physicians and scientists collaborate with industry to advance medical breakthroughs. These partnerships help commercialize discoveries for public benefit while maintaining scientific integrity. To ensure transparency and minimize potential bias, Cleveland Clinic reviews these relationships and publicly discloses when physicians/scientists receive significant compensation for consulting, serve in fiduciary roles, receive royalties, or hold equity interests related to their work. We manage potential conflicts through approval processes, annual reporting, and targeted management plans.

As of 2026-01-08, Dr. Petros has reported no financial relationship with industry that is applicable to this listing.

In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by Cleveland Clinic. To learn more about Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.

Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers' discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias.

* Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.